BMRA — Biomerica Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro CapNeutral
- $42.54m
- $32.37m
- $7.20m
- 36
- 29
- 52
- 32
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 82.75 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.36 | ||
| Price to Tang. Book | 4.54 | ||
| Price to Free Cashflow | 16.67 | ||
| Price to Sales | 2.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.44% | ||
| Return on Equity | -51.52% | ||
| Operating Margin | -35.98% | ||
Financial Summary
| Year End 31st May | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.79 | 5.56 | 5.2 | 6.69 | 7.2 | 10.95 | 11.69 | 6.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biomerica, Inc., (Biomerica) is a biomedical technology company. The Company develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The Company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The Company is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.
Directors
- Zackary Irani CHM (55)
- Allen Barbieri VCH (63)
- Steven Sloan CFO (51)
- Catherine Coste IND (55)
- Jane Emerson IND (67)
- Mark Sirgo IND (67)
- Last Annual
- May 31st, 2021
- Last Interim
- February 28th, 2022
- Incorporated
- September 22nd, 1971
- Public Since
- March 23rd, 2009
- No. of Shareholders
- 800
- No. of Employees
- 49
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 12,851,924
- Address
- 17571 von Karman Ave, IRVINE, 92614-6207
- Web
- http://www.biomerica.com/
- Phone
- +1 9496452111
- Auditors
- PKF Certified Public Accountants
Upcoming Events for BMRA
Q1 2023 Biomerica Inc Earnings Release
Biomerica Inc Annual Shareholders Meeting
Q2 2023 Biomerica Inc Earnings Release
Similar to BMRA
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
Allied Healthcare Products
NASDAQ Capital Market
FAQ
What is the Biomerica share price?
As of Today at 05:55 UTC, shares in Biomerica are trading at $3.31. This share price information is delayed by 15 minutes.
How has the Biomerica share price performed this year?
Shares in Biomerica last closed at $3.31 and the price had moved by -15.99% over the past 365 days. In terms of relative price strength the Biomerica share price has underperformed the S&P500 Index by -10.06% over the past year.
What are the analyst and broker recommendations for Biomerica?
The overall consensus recommendation for Biomerica is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biomerica dividend yield?
Biomerica does not currently pay a dividend.
Does Biomerica pay a dividend?
Biomerica does not currently pay a dividend.
When does Biomerica next pay dividends?
Biomerica does not currently pay a dividend.
How do I buy Biomerica shares?
To buy shares in Biomerica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biomerica?
As of the previous close price of $3.31, shares in Biomerica had a market capitalisation of $42.54m.
Where are Biomerica shares listed?
Here are the trading details for Biomerica:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BMRA
What kind of share is Biomerica?
Based on an overall assessment of its quality, value and momentum Biomerica is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biomerica share price forecast for 2022?
The analyst consensus target price for shares in Biomerica is $13.00. That is 292.75% above the last closing price of $3.31.
Analysts covering Biomerica currently have a consensus Earnings Per Share (EPS) forecast of -$0.43 for the next financial year.
What is the trend in the Biomerica share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomerica. Over the past six months, its share price has underperformed the S&P500 Index by -17.6%.
As of the last closing price of $3.31, shares in Biomerica were trading -15.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biomerica PE Ratio?
The Biomerica PE ratio based on its reported earnings over the past 12 months is 82.75. The shares last closed at $3.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biomerica?
Biomerica's management team is headed by:
- Zackary Irani - CHM
- Allen Barbieri - VCH
- Steven Sloan - CFO
- Catherine Coste - IND
- Jane Emerson - IND
- Mark Sirgo - IND